Skip to main content
Premium Trial:

Request an Annual Quote

Product Watch: Enzymatics Sarcoma Fusion Assay

Premium

Enzymatics this week launched a targeted sequencing assay today for detecting and identifying fusions of 26 genes associated with sarcoma.

Using Enzymatics' proprietary anchored multiplex PCR-based enrichment, fusions of all genes in their panel can be identified in a single sequencing run, even without prior knowledge of fusion partners or breakpoints, the company said. The assay will join the ALK, RET, ROS1 v2 panel and the Heme panel as the newest addition to the Archer FusionPlex product line.

FusionPlex assays are target-enrichment assays used to create libraries for next-generation sequencing. They are FFPE-compatible, can be run on Illumina and Ion Torrent NGS platforms, and, in conjunction with Archer Universal RNA Fusion Detection Kits and MBC Adapters, can simultaneously detect and identify specific gene fusions, the company said.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.